Gilead Sciences, Inc. Will Probably Not Rush With The Vertex Pharmaceuticals Acquisition

There is a possibility that Gilead Sciences, Inc. (NASDAQ:GILD) may offer $45 billion to acquire Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) in an attempt to tap into the cystic fibrosis market. We at Bidness Etc, however, believe that Corbus Pharmaceuticals Holding Inc's (NASDAQ:CRBP) plans to begin Phase II trials for an experimental cystic fibrosis drug may slow down Gilead's plans to extend an acquisition offer.